Pre-made Pinatuzumab benchmark antibody ( Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-444

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-444 Category Tag

Product Details

Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pinatuzumab vedotin (DCDT2980S, FCU2703) is an anti-CD22 antibody-drug conjugate (ADC) developed by Genentech/ Hoffmann-La Roche for the treatment of diffuse large B-cell lymphoma (DLBCL). … Pinatuzumab vedotin has proved its efficacy in inducing a complete tumor regression in xenograft lymphoma models.

Products Name (INN Index)

Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody

INN Name

Pinatuzumab

Target

CD22

Format

Whole mAb ADC

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

6and:HL

95-98% SI Structure

None

Year Proposed

2012

Companies

Genentech

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Chronic lymphocytic leukaemia,Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD22

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide